Plasmodium vivax clinically resistant to chloroquine in Colombia

  • Soto J
  • Toledo J
  • Gutierrez P
 et al. 
  • 33

    Readers

    Mendeley users who have this article in their library.
  • 94

    Citations

    Citations of this article.

Abstract

Chloroquine-resistant Plasmodium vivax has been the subject of numerous case reports and prospective studies from Oceania and Asia. In contrast, only case reports exist from the Americas. We performed a prospective study with 28-day follow-up of clinical responses to chloroquine in 2 P. vivax-endemic regions of Colombia. Three (11%) of 27 patients failed to respond to treatment with the standard regimen of chloroquine (1,500 mg of base over 3 days). One patient demonstrated RI resistance on Day 26; one patient demonstrated RI resistance due to recrudescence of blood stages on Day 11; and one patient demonstrated RII resistance of blood stages by never displaying clearing of peripheral parasitemia. All patients were successfully treated with primaquine, which has some blood stage efficacy against P. vivax, combined with a second course of chloroquine. Clinical resistance of P. vivax to chloroquine is present in Colombia and should be monitored in the Americas.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • J. Soto

  • J. Toledo

  • P. Gutierrez

  • M. Luzz

  • N. Llinas

  • N. Cedeño

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free